Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Wockhardt Q1 net...

    Wockhardt Q1 net profit dives 83 percent to Rs 16 cr

    Written by savita thakur thakur Published On 2016-08-16T15:20:07+05:30  |  Updated On 16 Aug 2016 3:20 PM IST
    Wockhardt Q1 net profit dives 83 percent to Rs 16 cr

    Drug firm Wockhardt reported a fall of 82.65 per cent in consolidated net profit to Rs 15.89 crore for the first quarter ended June 30, mainly on account of dip in sales and increased expenditure.


    The company had posted a net profit after taxes, minority interest and share of profit of associates at Rs 91.61 crore in the same period a year ago, Wockhardt said in a BSE filing.


    Consolidated total income of the company also decreased to Rs 1,090.83 crore during the quarter under review as against Rs 1,138.87 crore in the year-ago period.


    The company's UK business (excluding one time opportunity) displayed strong performance and grew by 26 per cent in the first quarter as compared to the same period year ago, Wockhardt said.


    India business of the company grew by 10 per cent for the quarter under consideration as against the corresponding period of the last fiscal, it added.


    On the other hand, the company said, its US business contributed 18 per cent of the global revenues and fell by 16 per cent for the first quarter of the current fiscal.


    Emerging market business saw a fall of 16 per cent in the quarter under consideration. Irish business also fell by 18 per cent in terms of rupee in the first quarter of 2016-17.


    "International business contributed 62 per cent of the total revenues during Q1 of FY17," the company said.


    The company's three units one at Chikalthana, and two at Waluj have received Establishment Inspection Reports with observations, Wockhardt said.


    "The company has initiated required steps to address the concerns raised by USFDA and is putting all efforts to resolve the matter," it added.

    EIREstablishment Inspection ReportUS Food & Drug AdministrationUSFDAWockhardt
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok